Evaluation of a Three-Fluid Nozzle Spraying Process for Facilitating Spray Drying of Hydrophilic Polymers for the Creation of Amorphous Solid Dispersions

Amorphous solid dispersions (ASDs) enable formulations to improve the solubility of poorly soluble active pharmaceutical ingredients (APIs). The amorphous state is reached through the disruption of the crystalline lattice of an API resulting in an increased apparent solubility with faster disintegra...

Full description

Saved in:
Bibliographic Details
Main Authors: Lena Karin Mueller (Author), Laura Halstenberg (Author), Nicole Di Gallo (Author), Thomas Kipping (Author)
Format: Book
Published: MDPI AG, 2023-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ba5801baf0d04ab5aea32c84c92b9b05
042 |a dc 
100 1 0 |a Lena Karin Mueller  |e author 
700 1 0 |a Laura Halstenberg  |e author 
700 1 0 |a Nicole Di Gallo  |e author 
700 1 0 |a Thomas Kipping  |e author 
245 0 0 |a Evaluation of a Three-Fluid Nozzle Spraying Process for Facilitating Spray Drying of Hydrophilic Polymers for the Creation of Amorphous Solid Dispersions 
260 |b MDPI AG,   |c 2023-10-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15112542 
500 |a 1999-4923 
520 |a Amorphous solid dispersions (ASDs) enable formulations to improve the solubility of poorly soluble active pharmaceutical ingredients (APIs). The amorphous state is reached through the disruption of the crystalline lattice of an API resulting in an increased apparent solubility with faster disintegration. Nevertheless, this form is characterized by a high-energy state which is prone to re-crystallization. To ensure a stable ASD, excipients, e.g., polymers that form a matrix in which an API is dispersed, are used. The applicable polymer range is usually linked to their solubility in the respective solvent, therefore limiting the use of hydrophilic polymers. In this work, we show the applicability of the hydrophilic polymer, polyvinyl alcohol (PVA), in spray-dried solid dispersions. Using a three-fluid nozzle approach, this polymer can be used to generate ASDs with a targeted dissolution profile that is characterized by a prominent spring and desired parachute effect showing both supersaturation and crystallization inhibition. For this purpose, the polymer was tested in formulations containing the weakly basic drug, ketoconazole, and the acidic drug, indomethacin, both classified as Biopharmaceutics Classification System (BSC) class II drugs, as well as the weakly basic drug ritonavir classified as BCS IV. Furthermore, ritonavir was used to show the enhanced drug-loading capacity of PVA derived from the advantageous viscosity profile that makes the polymer an interesting candidate for spray drying applications. 
546 |a EN 
690 |a polyvinyl alcohol 
690 |a amorphous solid dispersion 
690 |a spray drying 
690 |a spray-dried dispersion 
690 |a process development 
690 |a sustainability 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 11, p 2542 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/11/2542 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/ba5801baf0d04ab5aea32c84c92b9b05  |z Connect to this object online.